Maze Therapeutics (NASDAQ:MAZE) Insider Atul Dandekar Sells 7,500 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction that occurred on Thursday, January 29th. The shares were sold at an average price of $44.27, for a total value of $332,025.00. Following the completion of the transaction, the insider directly owned 10,503 shares of the company’s stock, valued at $464,967.81. This trade represents a 41.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Atul Dandekar also recently made the following trade(s):

• On Monday, December 29th, Atul Dandekar sold 72,400 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.56, for a total transaction of $2,936,544.00.
• On Tuesday, December 30th, Atul Dandekar sold 100 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.36, for a total transaction of $4,036.00.

Maze Therapeutics Price Performance

Shares of MAZE opened at $46.53 on Tuesday. Maze Therapeutics, Inc. has a 1-year low of $6.71 and a 1-year high of $47.36. The stock has a market cap of $2.24 billion and a PE ratio of -2.23. The firm has a fifty day moving average price of $41.05 and a 200 day moving average price of $29.37.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Institutional Trading of Maze Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. acquired a new position in Maze Therapeutics during the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. raised its holdings in Maze Therapeutics by 82.6% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after acquiring an additional 738 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Maze Therapeutics by 947.8% during the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after buying an additional 1,725 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Maze Therapeutics during the 3rd quarter worth about $52,000. Finally, CWM LLC purchased a new position in Maze Therapeutics during the second quarter worth approximately $28,000.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on MAZE shares. Guggenheim reaffirmed a “buy” rating and issued a $46.00 target price on shares of Maze Therapeutics in a report on Friday, December 19th. Wedbush boosted their target price on Maze Therapeutics from $35.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, November 7th. Raymond James Financial began coverage on shares of Maze Therapeutics in a research report on Thursday, November 13th. They issued an “outperform” rating and a $48.00 price objective on the stock. HC Wainwright restated a “buy” rating on shares of Maze Therapeutics in a research report on Wednesday, January 28th. Finally, BTIG Research boosted their price target on shares of Maze Therapeutics from $37.00 to $46.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $44.50.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.